SRPT Relative Valuation
SRPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SRPT is overvalued; if below, it's undervalued.
Historical Valuation
Sarepta Therapeutics Inc (SRPT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 4.77. The fair price of Sarepta Therapeutics Inc (SRPT) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：21.84
Fair
151.73
PE
1Y
3Y
5Y
Trailing
Forward
33.20
EV/EBITDA
Sarepta Therapeutics Inc. (SRPT) has a current EV/EBITDA of 33.20. The 5-year average EV/EBITDA is 2.75. The thresholds are as follows: Strongly Undervalued below -167.75, Undervalued between -167.75 and -82.50, Fairly Valued between 88.00 and -82.50, Overvalued between 88.00 and 173.25, and Strongly Overvalued above 173.25. The current Forward EV/EBITDA of 33.20 falls within the Historic Trend Line -Fairly Valued range.
66.78
EV/EBIT
Sarepta Therapeutics Inc. (SRPT) has a current EV/EBIT of 66.78. The 5-year average EV/EBIT is 6.36. The thresholds are as follows: Strongly Undervalued below -76.17, Undervalued between -76.17 and -34.91, Fairly Valued between 47.62 and -34.91, Overvalued between 47.62 and 88.89, and Strongly Overvalued above 88.89. The current Forward EV/EBIT of 66.78 falls within the Overvalued range.
1.50
PS
Sarepta Therapeutics Inc. (SRPT) has a current PS of 1.50. The 5-year average PS is 6.80. The thresholds are as follows: Strongly Undervalued below 0.09, Undervalued between 0.09 and 3.44, Fairly Valued between 10.15 and 3.44, Overvalued between 10.15 and 13.50, and Strongly Overvalued above 13.50. The current Forward PS of 1.50 falls within the Undervalued range.
21.64
P/OCF
Sarepta Therapeutics Inc. (SRPT) has a current P/OCF of 21.64. The 5-year average P/OCF is -3.46. The thresholds are as follows: Strongly Undervalued below -361.99, Undervalued between -361.99 and -182.72, Fairly Valued between 175.81 and -182.72, Overvalued between 175.81 and 355.08, and Strongly Overvalued above 355.08. The current Forward P/OCF of 21.64 falls within the Historic Trend Line -Fairly Valued range.
23.78
P/FCF
Sarepta Therapeutics Inc. (SRPT) has a current P/FCF of 23.78. The 5-year average P/FCF is -133.02. The thresholds are as follows: Strongly Undervalued below -1353.30, Undervalued between -1353.30 and -743.16, Fairly Valued between 477.12 and -743.16, Overvalued between 477.12 and 1087.26, and Strongly Overvalued above 1087.26. The current Forward P/FCF of 23.78 falls within the Historic Trend Line -Fairly Valued range.
Sarepta Therapeutics Inc (SRPT) has a current Price-to-Book (P/B) ratio of 1.73. Compared to its 3-year average P/B ratio of 11.81 , the current P/B ratio is approximately -85.32% higher. Relative to its 5-year average P/B ratio of 11.88, the current P/B ratio is about -85.41% higher. Sarepta Therapeutics Inc (SRPT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -8.22%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.65% , the current FCF yield is about -100.00% lower.
1.81
P/B
Median3y
11.81
Median5y
11.88
-16.65
FCF Yield
Median3y
-8.22
Median5y
-7.65
Competitors Valuation Multiple
The average P/S ratio for SRPT's competitors is 0.00, providing a benchmark for relative valuation. Sarepta Therapeutics Inc Corp (SRPT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -14.52%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SRPT decreased by 81.23% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.08 to -8.24.
The secondary factor is the Revenue Growth, contributed -14.52%to the performance.
Overall, the performance of SRPT in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Sarepta Therapeutics Inc (SRPT) currently overvalued or undervalued?
What is Sarepta Therapeutics Inc (SRPT) fair value?
How does SRPT's valuation metrics compare to the industry average?
What is the current P/B ratio for Sarepta Therapeutics Inc (SRPT) as of Dec 05 2025?
What is the current FCF Yield for Sarepta Therapeutics Inc (SRPT) as of Dec 05 2025?
What is the current Forward P/E ratio for Sarepta Therapeutics Inc (SRPT) as of Dec 05 2025?